参乌益肾片六种活性成分在正常与慢性肾衰大鼠中的比较药代动力学
本研究建立UPLC-TSQ-MS/MS法测定大鼠血浆中参乌益肾片六种活性成分,比较正常与腺嘌呤诱导慢性肾衰大鼠的药代动力学。正常大鼠中六种成分吸收迅速(Tmax≤2 h),约80%总暴露在10 h内消除;慢性肾衰大鼠消除减慢,AUC或Cmax显著改变。
要点
- 建立并验证了同时测定六种成分的UPLC-TSQ-MS/MS方法。
- 正常大鼠中白花素、植物胍基酸和大黄酸的AUC0-t与Cmax呈线性药代动力学。
- 慢性肾衰大鼠六种成分消除减慢,AUC或Cmax显著改变。
核心结论
- 参乌益肾片六种活性成分在慢性肾衰大鼠中消除减慢,AUC或Cmax显著改变,可能反映肾清除率下降或肝与胃肠药物代谢酶和转运体受抑制。
- 本研究首次报道参乌益肾片的药代动力学,为后续药代-药效关联及临床应用研究提供信息。
研究设计与样本
- 研究采用正常大鼠与腺嘌呤诱导的慢性肾衰大鼠,口服参乌益肾片后不同时间点采集血浆。
- 建立并验证UPLC-TSQ-MS/MS法测定血浆中白花素、芍药苷、植物胍基酸、大黄酸、芦荟大黄素和大黄素六种成分。
主要发现
- 方法线性良好(r ≥ 0.9913),精密度RSD <11.5%,准确度RE为-13.4∼13.1%,提取回收率、基质效应和稳定性RSD <15%。
- 正常大鼠中六种成分吸收迅速(Tmax ≤ 2 h),约80%总暴露在10 h内消除。
- 正常大鼠中白花素、植物胍基酸和大黄酸的AUC0-t与Cmax在剂量范围内呈线性药代动力学,芍药苷呈非线性。
- 慢性肾衰大鼠中六种成分消除减慢,AUC或Cmax值与正常大鼠显著不同。
临床怎么用
- 慢性肾衰病理状态可改变参乌益肾片多成分的药代动力学,临床用药时需考虑肾功能对药物暴露的影响。
- 该药代动力学结果可为参乌益肾片在慢性肾衰患者中的剂量调整和进一步药代-药效关联研究提供参考。
局限性
- 研究基于腺嘌呤诱导的慢性肾衰大鼠模型,结果外推至临床患者需谨慎。
- 原文未报告具体剂量、样本量、P值及详细药代参数数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Shen-Wu-Yi-Shen tablets (SWYST), a Chinese patent medicine consisting of 12 herbal medicines, was formulated by a famous TCM nephrologist, Zou Yunxiang. It is clinically used to improve the symptoms of nausea, vomiting, poor appetite, dry mouth and throat, and dry stool in patients with chronic renal failure (CRF) accompanied by qi and yin deficiency, dampness, and turbidity. SWYST can reduce urea nitrogen, blood creatinine, and urinary protein loss, and increase the endogenous creatinine clearance rate. However, little is known about its pharmacokinetics. AIM OF STUDY: To compare the pharmacokinetics of six bioactive components after oral administration of SWYST in normal and adenine-induced CRF rats. MATERIALS AND METHODS: A method based on ultra-performance liquid chromatography coupled with a triple-stage quadrupole mass spectrometer (UPLC-TSQ-MS/MS) was developed and validated to determine the six bioactive compounds (albiflorin, paeoniflorin, plantagoguanidinic acid, rhein, aloe-emodin, and emodin) in rat plasma. Rat plasma samples were prepared using protein precipitation. Chromatography was performed on an Agilent Eclipse Plus C18 column (3.0 × 50 mm, 1.8 μm) using gradient elution with a mobile phase composed of acetonitrile and water containing 0.1% (v/v) formic acid, while detection was achieved by electrospray ionization MS under the multiple selective reaction monitoring modes. After SWYST administration, rat plasma was collected at different time points, and the pharmacokinetic parameters of six analytes were calculated and analyzed based on the measured plasma concentrations. RESULTS: The UPLC-TSQ-MS/MS method was fully validated for its satisfactory linearity (r ≥ 0.9913), good precisions (RSD <11.5%), and accuracy (RE: -13.4∼13.1%), as well as acceptable limits in the extraction recoveries, matrix effects, and stability (RSD <15%). In normal rats, the six analytes were rapidly absorbed (Tmax ≤ 2 h), and approximately 80% of their total exposure was eliminated within 10 h. Moreover, in normal rats, the AUC0-t and Cmax of albiflorin, plantagoguanidinic acid, and rhein exhibited linear pharmacokinetics within the dose ranges, while that of paeoniflorin is non-linear. However, in CRF rats, the six analytes exhibited reduced elimination and significantly different AUC or Cmax values. These changes may reflect a decreased renal clearance rate or inhibition of drug-metabolizing enzymes and transporters in the liver and gastrointestinal tract caused by CRF. CONCLUSIONS: A sensitive UPLC-TSQ-MS/MS method was validated and used to investigate the pharmacokinetics of SWYST in normal and CRF rats. This is the first study to investigate the pharmacokinetics of SWYST, and our findings elucidate the causes of their different pharmacokinetic behaviors in CRF rats. Furthermore, the results provide useful information to guide further research on the pharmacokinetic-pharmacodynamic correlation and clinical application of SWYST.
引用
- Mei Y, Tong X, Hu Y, et al. Comparative pharmacokinetics of six bioactive components of Shen-Wu-Yi-Shen tablets in normal and chronic renal failure rats based on UPLC-TSQ-MS/MS. J Ethnopharmacol. 2023. PMID: 37348793. doi:10.1016/j.jep.2023.116818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。